Saverio Candido

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/7781950/publications.pdf

Version: 2024-02-01

83 papers	4,400 citations	117625 34 h-index	110387 64 g-index
83 all docs	83 docs citations	83 times ranked	7448 citing authors

#	Article	IF	Citations
1	Overactivation of IL6 cisâ€'signaling in leukocytes is an inflammatory hallmark of deep vein thrombosis. Molecular Medicine Reports, 2022, 25, .	2.4	4
2	The PIK3CA H1047R Mutation Confers Resistance to BRAF and MEK Inhibitors in A375 Melanoma Cells through the Cross-Activation of MAPK and PI3Kâ€"Akt Pathways. Pharmaceutics, 2022, 14, 590.	4.5	11
3	Co-Occurrence of Interleukin-6 Receptor Asp358Ala Variant and High Plasma Levels of IL-6: An Evidence of IL-6 Trans-Signaling Activation in Deep Vein Thrombosis (DVT) Patients. Biomolecules, 2022, 12, 681.	4.0	6
4	Nitric Oxide in Hematological Cancers: Partner or Rival?. Antioxidants and Redox Signaling, 2021, 34, 383-401.	5.4	10
5	Sensitivity of pancreatic cancer cells to chemotherapeutic drugs, signal transduction inhibitors and nutraceuticals can be regulated by WT-TP53. Advances in Biological Regulation, 2021, 79, 100780.	2.3	6
6	Interaction between matrix metalloproteinase-9 (MMP-9) and neutrophil gelatinase-associated lipocalin (NGAL): A recent evolutionary event in primates. Developmental and Comparative Immunology, 2021, 116, 103933.	2.3	3
7	Pomegranate: A promising avenue against the most common chronic diseases and their associated risk factors (Review). International Journal of Functional Nutrition, 2021, 2, .	1.3	15
8	GSK-3Î² Can Regulate the Sensitivity of MIA-PaCa-2 Pancreatic and MCF-7 Breast Cancer Cells to Chemotherapeutic Drugs, Targeted Therapeutics and Nutraceuticals. Cells, 2021, 10, 816.	4.1	19
9	YY1 Silencing Induces 5-Fluorouracil-Resistance and BCL2L15 Downregulation in Colorectal Cancer Cells: Diagnostic and Prognostic Relevance. International Journal of Molecular Sciences, 2021, 22, 8481.	4.1	8
10	Novel Insights into Epigenetic Regulation of IL6 Pathway: In Silico Perspective on Inflammation and Cancer Relationship. International Journal of Molecular Sciences, 2021, 22, 10172.	4.1	29
11	Effects of the MDM2 inhibitor Nutlin-3a on sensitivity of pancreatic cancer cells to berberine and modified berberines in the presence and absence of WT-TP53. Advances in Biological Regulation, 2021, , 100840.	2.3	4
12	Abilities of Î²-Estradiol to interact with chemotherapeutic drugs, signal transduction inhibitors and nutraceuticals and alter the proliferation of pancreatic cancer cells. Advances in Biological Regulation, 2020, 75, 100672.	2.3	9
13	Therapeutic resistance in breast cancer cells can result from deregulated EGFR signaling. Advances in Biological Regulation, 2020, 78, 100758.	2.3	21
14	Cutaneous melanoma and the immunotherapy revolution (Review). International Journal of Oncology, 2020, 57, 609-618.	3.3	75
15	Droplet Digital PCR Analysis of Liquid Biopsy Samples Unveils the Diagnostic Role of hsa-miR-133a-3p and hsa-miR-375-3p in Oral Cancer. Biology, 2020, 9, 379.	2.8	30
16	Cancer therapy and treatments during COVID-19 era. Advances in Biological Regulation, 2020, 77, 100739.	2.3	30
17	Role of the Transcription Factor Yin Yang 1 and Its Selectively Identified Target Survivin in High-Grade B-Cells Non-Hodgkin Lymphomas: Potential Diagnostic and Therapeutic Targets. International Journal of Molecular Sciences, 2020, 21, 6446.	4.1	7
18	Patient-Derived Tumor Organoids for Drug Repositioning in Cancer Care: A Promising Approach in the Era of Tailored Treatment. Cancers, 2020, 12, 3636.	3.7	23

#	Article	IF	Citations
19	Targeting GSK3 and Associated Signaling Pathways Involved in Cancer. Cells, 2020, 9, 1110.	4.1	146
20	Functional Roles of Matrix Metalloproteinases and Their Inhibitors in Melanoma. Cells, 2020, 9, 1151.	4.1	78
21	Influences of TP53 and the anti-aging DDR1 receptor in controlling Raf/MEK/ERK and PI3K/Akt expression and chemotherapeutic drug sensitivity in prostate cancer cell lines. Aging, 2020, 12, 10194-10210.	3.1	15
22	Update of in vitro, in vivo and ex vivo fluoroâ€‘edenite effects on malignant mesothelioma: A systematic review (Review). Biomedical Reports, 2020, 13, 1-1.	2.0	13
23	Abstract 4836: Diagnostic and prognostic significance of microRNA modulation in oral cancer. , 2020, , .		0
24	Abstract 4687: Oncogenic role of the transcription factor YY1 and its target Survivin in non-Hodgkin's lymphoma. , 2020, , .		0
25	Direct oral anticoagulant treatment of deep vein thrombosis reduces IL-6 expression in peripheral mono-nuclear blood cells. Experimental and Therapeutic Medicine, 2020, 20, 237.	1.8	1
26	Direct oral anticoagulant treatment of deep vein thrombosis reduces ILâ€‘6 expression in peripheral monoâ€‘nuclear blood cells. Experimental and Therapeutic Medicine, 2020, 20, 1-1.	1.8	8
27	The analysis of miRNA expression profiling datasets reveals inverse microRNA patterns in glioblastoma and Alzheimer's disease. Oncology Reports, 2019, 42, 911-922.	2.6	70
28	Prediction of PD-L1 Expression in Neuroblastoma via Computational Modeling. Brain Sciences, 2019, 9, 221.	2.3	22
29	Identification of Novel MicroRNAs and Their Diagnostic and Prognostic Significance in Oral Cancer. Cancers, 2019, 11, 610.	3.7	94
30	Abilities of berberine and chemically modified berberines to interact with metformin and inhibit proliferation of pancreatic cancer cells. Advances in Biological Regulation, 2019, 73, 100633.	2.3	25
31	Prognostic significance of deregulated microRNAs in uveal melanomas. Molecular Medicine Reports, 2019, 19, 2599-2610.	2.4	69
32	EpiMethEx: a tool for large-scale integrated analysis in methylation hotspots linked to genetic regulation. BMC Bioinformatics, 2019, 19, 385.	2.6	6
33	Effects of the MDM-2 inhibitor Nutlin-3a on PDAC cells containing and lacking WT-TP53 on sensitivity to chemotherapy, signal transduction inhibitors and nutraceuticals. Advances in Biological Regulation, 2019, 72, 22-40.	2.3	10
34	Pericytes in Microvessels: From â€œMuralâ€•Function to Brain and Retina Regeneration. International Journal of Molecular Sciences, 2019, 20, 6351.	4.1	79
35	Gut Microbiota and Cancer: From Pathogenesis to Therapy. Cancers, 2019, 11, 38.	3.7	378
36	Abilities of berberine and chemically modified berberines to inhibit proliferation of pancreatic cancer cells. Advances in Biological Regulation, 2019, 71, 172-182.	2.3	34

#	Article	IF	Citations
37	Metformin influences drug sensitivity in pancreatic cancer cells. Advances in Biological Regulation, 2018, 68, 13-30.	2.3	45
38	Cutaneous melanoma: From pathogenesis to therapy (Review). International Journal of Oncology, 2018, 52, 1071-1080.	3.3	281
39	Effects of berberine, curcumin, resveratrol alone and in combination with chemotherapeutic drugs and signal transduction inhibitors on cancer cellsâ€"Power of nutraceuticals. Advances in Biological Regulation, 2018, 67, 190-211.	2.3	23
40	MMP-9 as a Candidate Marker of Response to BRAF Inhibitors in Melanoma Patients With BRAFV600E Mutation Detected in Circulating-Free DNA. Frontiers in Pharmacology, 2018, 9, 856.	3.5	68
41	Introduction of WT-TP53 into pancreatic cancer cells alters sensitivity to chemotherapeutic drugs, targeted therapeutics and nutraceuticals. Advances in Biological Regulation, 2018, 69, 16-34.	2.3	27
42	Roles of p53, NF-ÎºB and the androgen receptor in controlling NGAL expression in prostate cancer cell lines. Advances in Biological Regulation, 2018, 69, 43-62.	2.3	21
43	Integrated analysis of colorectal cancer microRNA datasets: identification of microRNAs associated with tumor development. Aging, 2018, 10, 1000-1014.	3.1	135
44	Abstract 5305: DNA methylation and gene expression in melanoma: A large-scale integrated analysis. , 2018, , .		0
45	Regulation of GSK-3 activity by curcumin, berberine and resveratrol: Potential effects on multiple diseases. Advances in Biological Regulation, 2017, 65, 77-88.	2.3	39
46	Effects of resveratrol, curcumin, berberine and other nutraceuticals on aging, cancer development, cancer stem cells and microRNAs. Aging, 2017, 9, 1477-1536.	3.1	168
47	Roles of GSK-3 and microRNAs on epithelial mesenchymal transition and cancer stem cells. Oncotarget, 2017, 8, 14221-14250.	1.8	86
48	Environment and bladder cancer: molecular analysis by interaction networks. Oncotarget, 2017, 8, 65240-65252.	1.8	39
49	Targeting signaling and apoptotic pathways involved in chemotherapeutic drug-resistance of hematopoietic cells. Oncotarget, 2017, 8, 76525-76557.	1.8	17
50	Drug-resistance in doxorubicin-resistant FL5.12 hematopoietic cells: elevated MDR1, drug efflux and side-population positive and decreased BCL2-family member expression. Oncotarget, 2017, 8, 113013-113033.	1.8	8
51	Computational Modeling of PI3K/AKT and MAPK Signaling Pathways in Melanoma Cancer. PLoS ONE, 2016, 11, e0152104.	2.5	50
52	MMP-9 overexpression is associated with intragenic hypermethylation of MMP9 gene in melanoma. Aging, 2016, 8, 933-944.	3.1	67
53	Low levels of inflammation and the absence of subclinical atherosclerosis in rheumatoid arthritis. Molecular Medicine Reports, 2016, 13, 3521-3524.	2.4	7
54	Fluoro-edenite induces fibulin-3 overexpression in non-malignant human mesothelial cells. Oncology Letters, 2016, 12, 3363-3367.	1.8	24

#	Article	IF	Citations
55	Computational modeling in melanoma for novel drug discovery. Expert Opinion on Drug Discovery, 2016, 11, 609-621.	5.0	15
56	Correlation between the overexpression of Yin Yang 1 and the expression levels of miRNAs in Burkitt's lymphoma: A computational study. Oncology Letters, 2016, 11, 1021-1025.	1.8	53
57	Diagnostic value of neutrophil gelatinase-associated lipocalin/matrix metalloproteinase-9 pathway in transitional cell carcinoma of the bladder. Tumor Biology, 2016, 37, 9855-9863.	1.8	15
58	Roles of NGAL and MMP-9 in the tumor microenvironment and sensitivity to targeted therapy. Biochimica Et Biophysica Acta - Molecular Cell Research, 2016, 1863, 438-448.	4.1	79
59	Computational identification of microRNAs associated to both epithelial to mesenchymal transition and NGAL/MMP-9 pathways in bladder cancer. Oncotarget, 2016, 7, 72758-72766.	1.8	73
60	Critical Roles of EGFR Family Members in Breast Cancer and Breast Cancer Stem Cells: Targets for Therapy. Current Pharmaceutical Design, 2016, 22, 2358-2388.	1.9	34
61	Roles of EGFR and KRAS and their downstream signaling pathways in pancreatic cancer and pancreatic cancer stem cells. Advances in Biological Regulation, 2015, 59, 65-81.	2.3	121
62	Roles of signaling pathways in drug resistance, cancer initiating cells and cancer progression and metastasis. Advances in Biological Regulation, 2015, 57, 75-101.	2.3	100
63	Abstract 4304: MMP-9 as a marker of response to treatment with B-Raf inhibitors in cutaneous melanoma. , 2015, , .		0
64	Roles of neutrophil gelatinase-associated lipocalin (NGAL) in human cancer. Oncotarget, 2014, 5, 1576-1594.	1.8	91
65	Deregulation of the EGFR/PI3K/PTEN/Akt/mTORC1 pathway in breast cancer: possibilities for therapeutic intervention. Oncotarget, 2014, 5, 4603-4650.	1.8	231
66	Analysis of the B-RAFV600E mutation in cutaneous melanoma patients with occupational sun exposure. Oncology Reports, 2014, 31, 1079-1082.	2.6	44
67	Emerging targeted therapies for melanoma treatment (Review). International Journal of Oncology, 2014, 45, 516-524.	3.3	39
68	IL-6-174 G>C and MMP-9-1562 C>T polymorphisms are associated with increased risk of deep vein thrombosis in cancer patients. Cytokine, 2013, 62, 64-69.	3.2	27
69	A tailored health surveillance program unveils a case of MALT lymphoma in an HCV-positive health-care worker. Oncology Letters, 2013, 5, 651-654.	1.8	8
70	Neopterin: A potential marker in chronic peripheral arterial disease. Molecular Medicine Reports, 2013, 7, 1855-1858.	2.4	13
71	Abstract 4074: Transcription factors involved in the genesis and progression of cancer differently modulated by transforming growth factor-beta3 (TGF-Beta3) in prostate cell lines.. , 2013, , .		0
72	Gene alterations in the PI3K/PTEN/AKT pathway as a mechanism of drug-resistance (Review). International Journal of Oncology, 2012, 40, 639-44.	3.3	81

#	Article	IF	Citations
73	Ectopic NGAL expression can alter sensitivity of breast cancer cells to EGFR, Bcl-2, CaM-K inhibitors and the plant natural product berberine. Cell Cycle, 2012, 11, 4447-4461.	2.6	22
74	The tumor microenvironment in hepatocellular carcinoma (Review). International Journal of Oncology, 2012, 40, 1733-47.	3.3	111
75	microRNAs and thyroid cancer: Biological and clinical significance. International Journal of Molecular Medicine, 2012, 30, 991-999.	4.0	38
76	Molecular Targeted Therapy in Melanoma: A Way to Reverse Resistance to Conventional Drugs. Current Drug Delivery, 2012, 9, 17-29.	1.6	22
77	BRAF mutations in papillary thyroid carcinoma and emerging targeted therapies (Review). Molecular Medicine Reports, 2012, 6, 687-694.	2.4	25
78	Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR Cascade Inhibitors: How Mutations Can Result in Therapy Resistance and How to Overcome Resistance. Oncotarget, 2012, 3, 1068-1111.	1.8	279
79	Mutations and Deregulation of Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR Cascades Which Alter Therapy Response.. Oncotarget, 2012, 3, 954-987.	1.8	244
80	Nectin like-5 overexpression correlates with the malignant phenotype in cutaneous melanoma. Oncotarget, 2012, 3, 882-892.	1.8	107
81	Effects of Ectopic Expression of NGAL on Doxorubicin Sensitivity. Oncotarget, 2012, 3, 1236-1245.	1.8	13
82	Advances in Targeting Signal Transduction Pathways. Oncotarget, 2012, 3, 1505-1521.	1.8	41
83	Prevalence of hepatitis C virus infection among health-care workers: A 10-year survey. Molecular Medicine Reports, 2010, 3, 561-4.	2.4	11